Sociedad Americana de Hirudoterapia

On the isolation of the thrombin inhibitor hirudin

Research article published in Thromb Res (1985)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Farmacología salivalDesarrollo de fármacosWalsmann P et al. · Thromb Res, 1985

Abstract

A procedure for isolation of hirudin from crude preparations was described. By the use of ion exchange chromatography and affinity chromatography preparations were obtained with a specific activity of 10 to 15 antithrombin units/micrograms. Separation into several fractions with the same activity suggests the existence of isoinhibitors.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsCattleChromatography, AffinityChromatography, Ion ExchangeElectrophoresis, Polyacrylamide GelHirudinsKineticsLeechesThrombin

Resumen

Procedure for hirudin isolation from crude preparations using ion exchange and affinity chromatography; specific activity of 10-15 antithrombin units/microgram with separation into multiple isoinhibitors.

Por qué esto importa para la hirudoterapia

This article describes a laboratory procedure for isolating hirudin from crude preparations using ion exchange and affinity chromatography, achieving specific activities of 10–15 antithrombin units per microgram. Separation yielded several fractions with equivalent activity, leading the authors to suggest the existence of isoinhibitors. This work is relevant to ASH's domain only in the narrow biochemical sense of hirudin purification and the structural diversity of its active forms. The abstract provides no clinical, in-vivo, or therapeutic data, does not mention leeches, and its relevance is limited to methodology and biochemical characterization.

Citación

On the isolation of the thrombin inhibitor hirudin.

Walsmann P et al. · Thromb Res, 1985

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Salivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.